Antigen-specific therapies for the treatment of multiple sclerosis: a clinical trial update.

about

Antigen-specific therapy of rheumatoid arthritis

P2860

Q57674015-B06F18B4-B93C-4F8D-9059-AFEDF7E4CA2A

P2860

Antigen-specific therapies for the treatment of multiple sclerosis: a clinical trial update.

Item

http://www.wikidata.org/entity/Q36179710

description

1997 nî lūn-bûn

@nan

1997年の論文

@ja

1997年論文

@yue

1997年論文

@zh-hant

1997年論文

@zh-hk

1997年論文

@zh-mo

1997年論文

@zh-tw

1997年论文

@wuu

1997年论文

@zh

1997年论文

@zh-cn

name

Antigen-specific therapies for ...... osis: a clinical trial update.

@ast

Antigen-specific therapies for ...... osis: a clinical trial update.

@en

type

Item

label

Antigen-specific therapies for ...... osis: a clinical trial update.

@ast

Antigen-specific therapies for ...... osis: a clinical trial update.

@en

prefLabel

Antigen-specific therapies for ...... osis: a clinical trial update.

@ast

Antigen-specific therapies for ...... osis: a clinical trial update.

@en

P1476

Antigen-specific therapies for ...... osis: a clinical trial update.

@en

P2093

Spack EG

http://www.w3.org/2001/XMLSchema#string

P2860

Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group

Fine specificity of the antibody response to myelin basic protein in the central nervous system in multiple sclerosis: the minimal B-cell epitope and a model of its features.

Binding of myelin basic protein peptides to human histocompatibility leukocyte antigen class II molecules and their recognition by T cells from multiple sclerosis patients

Prevention of experimental autoimmune encephalomyelitis by antibodies against interleukin 12.

Cytokine-induced immune deviation as a therapy for inflammatory autoimmune disease.

Reversal of experimental autoimmune encephalomyelitis by a soluble peptide variant of a myelin basic protein epitope: T cell receptor antagonism and reduction of interferon gamma and tumor necrosis factor alpha production

Local delivery of interleukin 4 by retrovirus-transduced T lymphocytes ameliorates experimental autoimmune encephalomyelitis.

Myelin basic protein-specific T helper 2 (Th2) cells cause experimental autoimmune encephalomyelitis in immunodeficient hosts rather than protect them from the disease.

Suppressor T cells generated by oral tolerization to myelin basic protein suppress both in vitro and in vivo immune responses by the release of transforming growth factor beta after antigen-specific triggering

T cell vaccination: clinical application in autoimmune diseases.

P304

1715-1727

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1517/13543784.6.11.1715

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

1997-11-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

15989576

http://www.w3.org/2001/XMLSchema#string

Antigen-specific therapies for the treatment of multiple sclerosis: a clinical trial update.

about

P2860

P2860

Antigen-specific therapies for the treatment of multiple sclerosis: a clinical trial update.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P698

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P698